REGEnLIFE is a medtech based in Montpellier at an advanced clinical stage and positioned on the treatment of neurodegenerative diseases. It is developing a patented therapeutic solution based on biophotonics. This innovative approach is based on a neurostimulation approach based on near-infrared light emissions. The objective is to act on neuroinflammation by stimulating the mitochondria, the “factory” of the cell, by targeting complex IV of the respiratory chain. This non-invasive and painless application for the patient takes the form of a helmet and an abdominal belt to target both the brain and the intestine. Recent scientific studies suggest, in fact, the key role of the brain-intestine-microbiota axis in the development of neurodegenerative diseases.
La société a levé +8M€ depuis sa création dans le cadre de sa R&D et ses développements cliniques sur la maladie d’Alzheimer et les commotions cérébrales liées au sport.
This neurotech is positioned in the global neurostimulation market valued at $20 billion in 2022 and with strong growth potential, which is estimated at 20% between 2023 and 2028 (sources: Reports Insights Consulting).
REGEnLIFE launched its pivotal clinical study Light4life, carried out in partnership with the Gérontopôle of the University Hospital Center of Toulouse, it will be carried out until 2025 with 108 patients aged 55 to 85 years old and suffering from mild to moderate Alzheimer’s disease. Patients will be treated and randomly divided into two groups: one will benefit from the REGEnLIFE device and the other from an inactive device (placebo-sham). The first results are planned for 2025.
A first clinical trial pilot carried out between 2018 and 2020 in around fifty patients aged 55 to 85 years old and suffering from mild to moderate Alzheimer's disease, demonstrated the safety, ease of use of the treatment and an improvement in certain cognitive functions of patients in just two months of intervention, a very short time compared to treatments available on the market or currently under development. These results were published in November 2022 in the Journal of Alzheimer’s Disease.
At the same time, REGEnLIFE has just completed a pilot study at the Georges Pompidou hospital on concussions in sport. The results are currently being analyzed. Often trivialized, these common but complex pathologies are likely to ultimately lead to significant cognitive disorders, or even chronic neurological diseases.
REGEnLIFE leads today:
- A pivotal phase 3 clinical study in Alzheimer’s disease
- A Phase 2 Pilot Clinical Study on Concussions
- New clinical developments in neurology, particularly in diseases such as depression and multiple sclerosis